I
nterleukin-1␤ is a crucial mediator of host defense and is implicated in the pathogenesis of many inflammatory diseases (1) . Unlike classical secretory proteins, IL-1␤ lacks a secretory signal sequence and is externalized through a "leaderless" pathway (2) . The mechanism of IL-1␤ secretion can be divided in two steps (3) (4) (5) . In the first step, microbial products such as pathogen-associated molecular pattern molecules (PAMPs) 4 induce gene expression and accumulation of the precursor protein pro-IL-1␤. In the second step, stimuli such as extracellular ATP, crystals (monosodium urate crystals), or pathogenic dusts (asbestos or silica) trigger assembly of the multiprotein complex inflammasome (6) with activation of IL-1␤-converting enzyme/ caspase-1, ultimately responsible for the cleavage and secretion of the cytokine. Although the second signal increases and accelerates IL-1␤ processing and secretion, in human monocytes stimulation by PAMPs is sufficient to drive secretion of mature IL-1␤, because triggering of pathogen recognition receptors such as TLRs or nucleotide oligomerization domain (NOD) 2 causes the release of endogenous ATP (7) . The autocrine stimulation of the purinergic receptor P2X7 (8) by the released ATP is then responsible for the cascade of events that leads to maturation and secretion of IL-1␤ (7) .
Although various targets of extracellular signals as well as molecular events involved in inflammasome assembly have been identified, the mechanisms underlying caspase-1 activation and IL-1␤ processing and secretion are still partially unclear (9) . Recently, much interest has been put on the role of redox in IL-1␤ secretion. It is generally accepted that the engagement of various TLRs induces activation of phagosomal NADPH oxidase (10 -12) with generation of reactive oxygen species (ROS) that concur to regulate NF-B activity and to induce inflammatory cytokine gene expression, including IL-1␤ (13) . Differently, contrasting observations have been reported on the role of redox in the posttranslational control of IL-1␤ production, following ATP stimulation. Some reports proposed that ROS, produced by NADPH oxidase following exposure to exogenous ATP, concur to activate caspase-1 (14 -16). Dostert et al. (16) also suggested that ROS detoxifying proteins such as thioredoxin (Trx) negatively regulate inflammasome activation. In contrast, Meissner et al. (17) proposed that ROS specifically inhibit ATP-induced caspase-1 activation by oxidation and glutathionylation of two redox-sensitive cysteine residues and that this inhibition is reverted by superoxide dismutase 1 (SOD1).
Redox unbalance due to oxidative stress is common in many forms of cell stress (18) . However, healthy cells are equipped with systems that allow them to rapidly respond to the oxidative hit restoring the redox homeostasis (19) . These systems include ROS scavengers and antioxidant enzymes such as SOD1, catalase, glutathione (GSH), peroxidase, GSH reductase, and the Trx/Trx reductase system, as well as low-m.w. antioxidants such as GSH and cysteine. GSH is the prototypic and most abundant non protein thiol (NPSH) in eukaryotic cells (20) . Cysteine, although considered the main plasma antioxidant, is usually very low extracellularly, where the oxidized form (cystine) is predominant (21) . Cystine is transported inside cells by the anionic amino acid transport system x c Ϫ (22) . We have previously shown that, under certain conditions, extracellular cystine uptake through x c Ϫ increases, followed by intracellular reduction of the amino acid and release of cysteine, that causes the reduction of the extracellular medium (23) (24) (25) . The importance of this cystine/cysteine redox cycle in redox homeostasis has been recently highlighted: Banjac et al. (26) reported that, in lymphoma cells, a reducing extracellular environment generated by cysteine release is a more efficient defense against oxidative stress than intracellular GSH. Based on these premises, we made the hypothesis that IL-1␤ processing and secretion induced by PAMPs is regulated by a biphasic redox modulation. The results obtained support a model in which a first oxidative hit is followed by an antioxidant response necessary for secretion of mature, fully processed IL-1␤.
Materials and Methods

Chemicals
L-Buthionine-(S,R)-sulfoximine (BSO), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-chloro-2,4-dinitrobenzene (DNCB), diphenylene iodonium (DPI), 5,5Ј-dithiobis-(2-nitrobenzoic acid) (DTNB), DTT, L-glutamate, LPS, and zymosan were from Sigma-Aldrich; muramyl dipeptide (MDP) was from Calbiochem; and heat-inactivated Staphylococcus aureus was from Invitrogen. 2Ј,7Ј-dichlorofluorescein diacetate (H 2 DCF-DA) and monochlorobimane (MCB) were from Molecular Probes.
Cell cultures
Human monocytes from healthy donors were isolated and cultured as described (7) in the absence or presence of 1 g/ml LPS, 3 g/ml MDP, 10 7 heat-inactivated S. aureus per ml, or 50 g/ml zymosan (7). For silencing experiments, monocytes were isolated by the RosetteSep Human Monocyte enrichment mixture (Stem Cell Technologies) according to the manufacturer's instructions, and kept in culture with 20 ng/ml human IFN-␥ (Roche) for 24 h before stimulation with PAMPs. 
Intracellular ROS and GSH detection
Determination of NPSHs in culture media
Supernatants (0.1 ml) from monocytes cultured at 4 ϫ 10 5 /0.5 ml in 24-well plates in medium containing 5% FBS were reacted with 10 mM DTNB and the absorption measured at 412 nm (23) (24) (25) . To discriminate between extracellular cysteine and GSH, S-carboxymethyl derivatives of soluble thiols were generated as described (23) and NPSHs were separated by HPLC with a Bondapak NH 2 column (Warters). GSH, oxidized glutathione (Roche), cystine, and cysteine (Sigma-Aldrich) were used as external standards.
Western blot analysis
Triton X-100 cell lysates were resolved on 12% SDS-PAGE, and electrotransferred (7). Filters were probed with 3ZD anti-IL-1␤ mAb (IgG1; 
ELISA
IL-1␤ content in supernatants was determined by ELISA (R&D Systems) (7).
SOD1 and Trx silencing
Primary monocytes (10 ϫ 10 6 ) were nucleofected with 5 g of SOD1 or Trx siRNA (Invitrogen) according to the manufacturer's instructions (Amaxa Nucleofector Technology). Transfected cells were incubated for 24 h in the presence of 20 ng/ml IFN-␥ and then stimulated with 50 g/ml zymosan for additional 18 h.
Real-time PCR
Total RNA was isolated from cell by TriPure Isolation Reagent (Roche) and reverse-transcribed by Superscript III Reverse Transcriptase (Invitrogen) according to manufacturer's instructions. Real-time PCR determination of SOD1 and Trx cDNA was performed using SYBR Green ER qPCR Super Mix for iCycler reagent (Invitrogen) using the following primers: forward: 5Јtgaagagaggcatgttggag3Ј and reverse: 5Јatgatgcaatggtctcctga 3Ј (for SOD1); forward: 5Јagcagatcgagagcaagact3Ј and reverse: 5Јcactctgaag caacatcctg3Ј (for Trx); forward 5Јgaaggtgaaggtcggagtc3Ј and reverse 5Јca tgggtggaatcatattggaa3Ј (for GAPDH). Relative expression was determined using ⌬Ct method (29) .
Statistical analysis
The data were statistically analyzed by using one-way ANOVA test, followed by Bonferroni posttest, using GraphPad software.
Results
PAMP stimulation induces ROS production followed by release of reduced cysteine, required for IL-1␤ secretion
Agonists of different TLRs (LPS, zymosan, S. aureus) as well as the NOD2 ligand MDP induced expression of pro-IL-1␤ which was detectable in monocytes after 30 min or 1 h (depending on the stimulus, Zymosan being usually the fastest inducer) and intensified thereafter (Fig. 1A) . The plateau was reached at 3 h and maintained for ϳ18 h from stimulation. Processing and secretion of IL-1␤ were delayed, with little amounts of 17 kDa mature IL-1␤ detectable extracellularly at 3 h and increasing afterward, reaching a plateau at 18 h (Fig. 1B) . Fig. 1 . In BSO-treated monocytes, the total content of reduced GSH was decreased by 40%, while the small PAMP-induced GSH increase (see Fig. 1D ) was virtually abrogated. Data are expressed as percentage of secretion with respect to cells stimulated without L-glutamate and BSO (n ϭ 3). Fig. 1 (mean Ϯ SD,  n ϭ 3) . E, Intracellular pro-IL-1␤ in cell lysates of monocytes stimulated 18 h with LPS (lanes 1-3), MDP (lanes 4 -6), STAPH A (lanes 7-9) , or zymosan (ZYM, lanes 10 -12) in the absence (Ϫ, lanes 1, 4, 7, and 10) or presence of DNCB (lanes 2, 5, 8, and 11) or BCNU (lanes 3, 6, 9, and 12) . This Western blot is representative of five independent experiments. TLR triggering by PAMPs also induced generation of intracellular ROS, which peaked at 1 h, reaching levels up to four times higher than in unstimulated monocytes, and decreased thereafter (Fig. 1C) . Although some variability was observed among the different healthy donors (data not shown), the highest levels of ROS were most often induced by Zymosan and the lowest by LPS, with MDP and S. Aureus triggering intermediate levels (Fig. 1C) .
ROS production is generally counteracted by up-regulation of antioxidant defenses to avoid oxidative stress (18) . To characterize the antioxidant response occurring in monocytes following PAMP stimulation, we first analyzed the modulation of the two major nonenzymatic antioxidants, namely GSH and cysteine, at different times from PAMP stimulation. Intracellular GSH was only slightly higher in PAMP-stimulated than in resting monocytes at all times analyzed (Fig. 1D) . In contrast, the release of NPSHs was dramatically increased (up to 35 M), with kinetics similar to that of IL-1␤ secretion (Fig. 1B) , and reached the maximum level at 18 h (Fig. 1E) . HPLC analyses revealed that PAMP-induced NPSHs comprise mainly cysteine, whereas GSH was virtually absent (Fig. 1F) .
Culture in the presence of 2.5 mM L-glutamate, which impedes cystine uptake through the x c Ϫ antiporter, inhibited the release of cysteine by monocytes exposed to PAMPs ( Fig. 2A) , indicating that the release of reduced cysteine is dependent on the uptake of oxidized cystine from the medium. We then investigated whether monocyte antioxidant systems are implicated in the process of IL-1␤ maturation or secretion. As shown in Fig. 2B , inhibition of cysteine release by L-glutamate was paralleled by a dramatic decrease of IL-1␤ secretion. On the contrary, PAMP-induced cysteine release and IL-1␤ secretion were unaffected in monocytes depleted of GSH by exposure to the GSH synthesis inhibitor BSO (30) (Fig. 2, A and B) .
Thioredoxin is increased in PAMP-stimulated monocytes and is implicated in cysteine release and IL-1␤ secretion
We have previously shown that cysteine release by hemopoietic cells such as activated dendritic cells or B lymphocytes is paralleled by Trx increase and requires Trx activity (23, 25) . As shown in Fig. 3A , Trx was induced in monocytes by all PAMPs although at different extents and with different kinetics and reached the maximum intracellular accumulation at later times than pro-IL-1␤ (18 h; Fig. 3A) . Moreover, PAMP stimulation in the presence of DNCB, a specific inhibitor of Trx reductase (31), led to a strong impairment of both cysteine release (Fig. 3B) and IL-1␤ secretion (Fig. 3C ) without affecting significantly ROS generation (Fig. 3D) or pro-IL-1␤ biosynthesis (Fig. 3E) . Because DNCB as an inhibitor in fact converts Trx reductase into a NADPH oxidase, possibly resulting in increased levels of ROS (31), we also investigated the effects of BCNU, a different, broader inhibitor of intracellular oxidoreductases (32) . Exposure to BCNU gave results analogous to those obtained with DNCB (Fig. 3, B-E) .
Inhibition of NADPH oxidase prevents ROS production, antioxidant response, and IL-1␤ secretion: rescue by exogenous DTT
The above findings indicate that the reducing systems up-regulated by PAMPs, namely intracellular oxidoreductases and cysteine release, are implicated in IL-1␤ processing and secretion. To understand whether these reducing systems control IL-1␤ secretion independently of ROS, or PAMP-induced ROS are also required, the effects of the NADPH oxidase inhibitor DPI on up-regulation of Trx, cystine/cysteine redox cycle and IL-1␤ secretion were investigated. As shown in Fig. 4 , treatment with DPI inhibited ROS production (Fig. 4A) as well as the subsequent increase in Trx expression (Fig. 4B ) and cysteine release (Fig. 4C) . ROS inhibition also prevented the little increase in GSH induced by PAMPs (data not shown, see Fig. 1D ). Furthermore, while pro-IL-1␤ biosynthesis was unaffected or only slightly decreased by DPI treatment (Fig. 4E) , IL-1␤ secretion was completely blocked (Fig. 4D) .
Addition of DTT to extracellular medium increased PAMP-induced IL-1␤ secretion (Fig. 5, A and C) . More importantly, exogenous DTT reverted the DPI-mediated inhibition of IL-1␤ secretion (Fig. 5A) . The enhancing effects of DTT occur at posttranslational level, because pro-IL-1␤ expression and biosynthesis were only slightly affected, with a decrease in the expression rate (from 2-20% with the different PAMPs, data not shown), barely detectable at the level of pro-IL-1␤ cytoplasmic accumulation (Fig. 5B) . Extracellular DTT also reverted the inhibition of IL-1␤ secretion induced by BCNU or DNCB (Fig. 5C ).
IL-1␤ processing and secretion are impaired in monocytes silenced for Trx or SOD1
To substantiate the pharmacological data, human monocytes were nucleofected with siRNA specific for Trx. Moreover, because SOD1 has been shown involved in caspase-1 activation by second signals (17) , silencing of SOD1 was also performed. Knockout of either Trx (Fig. 6, A and B) or SOD1 (Fig. 6C ) resulted in a decreased IL-1␤ secretion (Fig. 6D) without affecting pro-IL-1␤ intracellular levels (Fig. 6B) .
Discussion
Although production of most cytokines is regulated mainly at the transcriptional level, a crucial step in the control of IL-1␤ secretion is located posttranslationally (1). Indeed, pro-IL-1␤ synthesis results in intracellular accumulation of a precursor devoid of biologic activity, and a complex series of events, only partially understood, are required to trigger processing and secretion of the mature, fully active cytokine. The results reported in this paper show that in primary human monocytes a biphasic redox response controls PAMP-induced IL-1␤ processing and secretion. First, ROS are generated soon after TLR or NOD2 engagement. Second, an antioxidant response is triggered with increased uptake of cystine, intracellular reduction of the amino acid and release of reduced cysteine. The cystine/cysteine redox cycle is fuctionally linked to the redox active enzyme Trx, which increases intracellularly following PAMP stimulation. Both the oxidative hit and the antioxidant response are required, because compounds inhibiting ROS generation, Trx reductase activity, or cystine uptake all prevent IL-1␤ secretion. However, the antioxidant step is the ultimate responsible for IL-1␤ processing and secretion, based on the following evidences: 1) pharmacologic inhibition of ROS generation by DPI inhibits PAMP-induced IL-1␤ processing and secretion and prevents Trx increase and cysteine externalization; 2) secretion of properly processed IL-1␤ in DPI-treated monocytes is restored by exogenous reducing agents such as DTT; and 3) exogenous DTT also rescues the inhibition of IL-1␤ secretion caused by drugs affecting oxidoreductase activity. Therefore, both events, oxidant and antioxidant, are required for PAMP-triggered IL-1␤ secretion, the role of ROS being the induction of the antioxidant response, necessary for IL-1␤ processing and secretion.
The antioxidant defense to an oxidative stress involves up-regulation of enzymatic and nonenzymatic antioxidant devises. Although oxidoreductases such as Trx were indeed up-regulated in PAMP-stimulated monocytes, GSH levels were barely increased. Moreover, GSH depletion did not affect the release of IL-1␤. These data suggest that PAMP-induced GSH increase is not crucial for the control of IL-1␤ secretion, although it cannot be ruled out whether GSH is required for other aspects in the antioxidant response to PAMP-induced stress, as proposed (33) .
Conversely, cysteine externalization with reduction of extracellular medium is strongly required, as inhibition of cysteine release by L-glutamate results in block of IL-1␤ processing and secretion. These findings support recent observations pointing to a crucial role of the cystine/cysteine cycle in redox related events such as lymphocyte activation and differentiation and cell survival to oxidative stress (23) (24) (25) (26) . Because L-glutamate hinders the uptake of cystine through the x c Ϫ antiporter, these data imply that PAMP-induced cysteine release involves uptake of cystine through x c Ϫ (22) . Moreover, our results indicate that the generation of a reducing extracellular environment allows IL-1␤ processing and secretion independently of whether the reducing milieu is engendered as an antioxidant response started intracellularly (with increased cystine/cysteine cycle, involving Trx/ Trx reductase activity) or by extracellular events, exemplified in our system by the addition of the reducing agent DTT.
The findings that both the oxidative hit and the antioxidant response are implicated in IL-1␤ secretion reconcile in part the contrasting observations reported by different groups on the relevant role of ROS and reductants on ATP-induced IL-1␤ secretion (14 -17) . In particular, Meissner et al. (17) proposed, based on SOD1-deficient mice, that ATP-induced processing and secretion in murine macrophages require a reduction of two caspase-1 cysteine residues. Our data support the contribution of SOD1 also in PAMP-induced IL-1␤ secretion, in the absence of exogenous second signals, and show the implication of Trx, suggesting that more than one antioxidant enzyme may exert activating functions on caspase-1. Indeed, the antioxidant response to stress involves more oxidoreductases (18) whose redundancy is justified by the crucial requirement of restoring the redox homeostasis after an oxidative stress. This is particularly true in inflammation, where PAMPs can trigger an exaggerated response, with hypersecretion of IL-1␤ leading to host death for septic shock (1) . In support to the involvement of different redox modulating enzymes in PAMP-triggered innate immunity, peroxiredoxin II has been shown to down-modulate LPS-induced ROS generation in macrophages thereby preventing excessive host responses to microbial products (34) .
Unlike in other studies on the redox modulation of IL-1␤ processing (14 -17), we did not add ATP or other exogenous supplies to monocyte cultures, because human monocytes, following PAMP stimulation, spontaneously release endogenous ATP, able to drive IL-1␤ processing and secretion (7) . Therefore, our system allows to define the role of redox in the absence of strong hits, such as high amount of extracellular ATP, that might cause an exaggerated, "nonphysiologic" oxidative stress.
Treatment with the NADPH oxidase inhibitor DPI did not significantly impair pro-IL-1␤ synthesis, suggesting that ROS levels after DPI treatment were still above the threshold level required to activate NF-B and pro-IL-1␤ gene expression. However, DPIinduced ROS inhibition dramatically impaired the antioxidant response (Trx and cystine/cysteine redox cycle) as well as IL-1␤ secretion. Therefore, the inhibition of IL-1␤ secretion occurs at the posttranslational level. Because in no cases intracellular accumulation of mature, 17 kDa IL-1␤ was detected, redox is likely to act on the mechanism of IL-1␤ processing. However, further studies are required to clarify whether redox operates only on the activation of inflammasome or also on the mechanism of IL-1␤ export.
Together, these observations indicate that redox modulation is an important step in the posttranslational control of IL-1␤ production and suggest that the redox state of the inflammatory microenvironment plays a crucial role in IL-1␤ secretion and hence in the propagation of inflammation. Microenvironment-derived IL-1␤ has been recently shown to promote tumor progression (35) . Moreover, neoplastic tissues display a more reduced environment than healthy tissues (24, 36) : this reduced milieu conceivably sustains and enhances secretion of IL-1␤. On these bases, microenvironmental redox represents a potential target not only for antiinflammatory but also for antitumor strategies (37) .
